Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Lung Neoplasms 9Glioblastoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Brenner Tumor 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Oligodendroglioma 3Carcinoma 3Astrocytoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mouth Neoplasms 2Medulloblastoma 2

Interventions

Magnetic Resonance Spectroscopy 10Cisplatin 10Specimen Handling 8Radiotherapy 6Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Paclitaxel 5Radiotherapy, Intensity-Modulated 4Fluorodeoxyglucose F18 4Biopsy 4Radiation 3Nivolumab 3Fluorouracil 3Carboplatin 3fludarabine phosphate 2fludarabine 2aldesleukin 2Taxes 2Radiosurgery 2Immunoglobulin G 2Gemcitabine 2Docetaxel 2Disulfides 2Cyclophosphamide 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2veliparib 1peposertib 1pembrolizumab 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Oropharyngeal Neoplasms × Immunoglobulin G × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡